Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $783,207 | $502,547 | $160,096 | $7,596 |
| % Growth | 55.8% | 213.9% | 2,007.6% | – |
| Cost of Goods Sold | $273,529 | $188,157 | $130,759 | $37,361 |
| Gross Profit | $509,678 | $314,390 | $29,337 | -$29,765 |
| % Margin | 65.1% | 62.6% | 18.3% | -391.9% |
| R&D Expenses | $121,031 | $128,844 | $57,857 | $34,135 |
| G&A Expenses | $121,653 | $78,985 | $49,128 | $34,919 |
| SG&A Expenses | $207,126 | $134,159 | $87,098 | $46,986 |
| Sales & Mktg Exp. | $85,473 | $54,867 | $37,970 | $5,891 |
| Other Operating Expenses | $99,391 | $270 | -$42,438 | $0 |
| Operating Expenses | $427,548 | $263,273 | $102,517 | $81,121 |
| Operating Income | $82,130 | $51,887 | -$91,930 | -$81,247 |
| % Margin | 10.5% | 10.3% | -57.4% | -1,069.6% |
| Other Income/Exp. Net | -$26,074 | $0 | -$6,692 | -$17,792 |
| Pre-Tax Income | $56,056 | $3,087 | -$98,622 | -$99,039 |
| Tax Expense | $6,137 | -$2,124 | $5,457 | -$18,529 |
| Net Income | $49,919 | $5,211 | -$104,079 | -$80,510 |
| % Margin | 6.4% | 1% | -65% | -1,059.9% |
| EPS | 0.15 | 0.016 | -0.34 | -0.29 |
| % Growth | 820.2% | 104.8% | -17.2% | – |
| EPS Diluted | 0.14 | 0.016 | -0.34 | -0.29 |
| Weighted Avg Shares Out | 331,226 | 319,181 | 310,644 | 282,206 |
| Weighted Avg Shares Out Dil | 345,188 | 323,710 | 310,644 | 282,206 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,862 | $694 | $1 | $163 |
| Interest Expense | $21,464 | $13,558 | $406 | $189 |
| Depreciation & Amortization | $5,686 | $6,743 | $5,379 | $5,174 |
| EBITDA | $98,233 | $22,966 | -$92,837 | -$70,073 |
| % Margin | 12.5% | 4.6% | -58% | -922.5% |